Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Incyte named former Karuna Therapeutics and Anthos Therapeutics exec Bill Meury as CEO. Vistagen appoints Elissa Cote as chief corporate development officer. Inizio Evoke, a 2025 MM+M Agency 100 ...

Neurocrine Biosciences' potential shines with robust assets, strong pipeline, and growth opportunities. Learn more about NBIX ...

“Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at rapid speed.

It just got a new CEO, Bill Meury. He’s an industry veteran, known as a deal maker. Makes sense. Meury was previously the CEO of Karuna Therapeutics, which he sold to Bristol Myers for a very nice ...

Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar commercial drugmaker it is today. Taking his place at the helm is Bill ...